02 Sep Evaluation of C1 esterase inhibitor concentrate for hereditary angioedema (2014)
The National Blood Authority (NBA) engaged HealthConsult to undertake an evaluation of C1 esterase inhibitor (C1-INH) concentrate for the management of hereditary angioedema (HAE). The evaluation included a review of the clinical evidence for the safety and effectiveness of C1-INH concentrate for the treatment of acute attacks and for routine and pre-procedural prophylaxis. The cost-effectiveness of C1-INH concentrate for these three indications, and the expected utilisation and financial implications for the National Product and Services List (NPSL) were also assessed. The evaluation was considered by the Medical Services Advisory Committee (MSAC) when it formulated its advice to the Jurisdictional Blood Committee on whether the product should be publicly funded through the NPSL. The project commenced in June 2014 and was completed in April 2015.